傅念,阳学风,孟令引,胡杨,彭飞.舒肝宁注射液治疗酒精性与非酒精性脂肪肝疗效观察.[J].中南医学科学杂志.,2011,39(2):180-182.
舒肝宁注射液治疗酒精性与非酒精性脂肪肝疗效观察
A Clinical Observation on the Efficacy of Shuganning Injection for Alcoholic and Nonalcoholic Fatty Liver Disease
投稿时间:2010-12-06  
DOI:
中文关键词:  酒精  脂肪肝  舒肝宁
英文关键词:alcoho  fatty liver  Shuganning
基金项目:
作者单位
傅念,阳学风,孟令引,胡杨,彭飞 南华大学附属南华医院 消化内科湖南 衡阳 421002 
摘要点击次数: 933
全文下载次数: 1314
中文摘要:
      目的观察比较舒肝宁注射液对酒精性脂肪肝与非酒精性脂肪肝的疗效。方法对22名酒精性脂肪肝(AFLD)患者和30名非酒精性脂肪肝(NAFLD)患者,均给予舒肝宁注射液20 mL,每日1次静脉滴注;对照组18例给予甘利欣注射液150 mg/日。疗程均为4周。检测各组治疗前后血清酶学、血脂等指标。结果两治疗组治疗后的血清天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转肽酶(GGT)、总胆红素(TBIL)、直接胆红素(DBIL)、甘油三酯(TG)、胆固醇(CHL)水平均比治疗前明显下降(P<0.01),且治疗组的改善程度优于对照组(P<0.01)。酒精性脂肪肝治疗组患者的疗效更为突出,与非酒精性脂肪肝治疗组比较差异有显著性(P<0.05)。结论舒肝宁注射液治疗脂肪肝,尤其是酒精性脂肪肝安全、有效,且具有一定的降血脂作用。
英文摘要:
      ObjectiveTo observ and compare clinical effect of Shuganning injection on AFLD and NAFLD.MethodsTwenty-two patients with AFLD and 30 with NAFLD which were treated with Shuganning injection in therapy group for 4 weeks,and 18 in control group with diammonium glycyrrhizinate for 4 weeks.Serum transaminase,blood lipid levels and other parameters in the two groups were detected before and after treatment.ResultsCompared with the control group,the levels of serum ALT,AST,GGT,TBIL,TG,CHL in treatment groups were obviously decreased (P<0.01).The effect was better in AFLD treatment group than in NAFLD treatment group(P<0.01).ConclusionShuganning injection is safe and effective in the treatment of fatty liver disease,especially AFLD,and it has certain function of depressing blood-lipid.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=6492C9B916B507EA5709A5BB3538817BF05D4A9FA8288E00E09D00F91FC1D9BE2D17EB1DA432DA86ECB10AD34B439A9A9A366F9ABC81DE3C22F05E83A069FE33F4BA7FCFD38347B85C137C655F30EECF2DF89843DAF2137D3FFD5850594C1CA442895536C665474247661C2C63C0420E57B8E805A97A0126&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=9377ED8094509821&aid=DD26710B4E10EE67123686C070FC6572&vid=&iid=0B39A22176CE99FB&sid=F1A8654ADB4E656E&eid=B1F98368A47B8888&fileno=20110217&flag=1&is_more=0">